Apolipoprotein E co-localizes with newly formed amyloid β-protein (Aβ) deposits lacking immunoreactivity against N-terminal epitopes of Aβ in a genotype-dependent manner

Acta Neuropathologica

Volumn 110, Issue 5, 2005, Pages 459-471

  Thal, Dietmar Rudolf ^a   Capetillo Zarate, Estibaliz ^a   Schultz, Christian ^b   Rüb, Udo ^b   Saido, Takaomi C ^c   Yamaguchi, Haruyasu ^d   Haass, Christian ^e   Griffin, W Sue T ^f   Del Tredici, Kelly ^b   Braak, Heiko ^b   Ghebremedhin, Estifanos ^b  

^a UNIVERSITY OF BONN   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c RIKEN BRAIN SCIENCE INSTITUTE   (Japan)

^d GUNMA UNIVERSITY   (Japan)

^e UNIVERSITY OF MUNICH   (Germany)

^f CENTRAL ARKANSAS VETERANS HEALTHCARE SYSTEM   (United States)

Author keywords

Alzheimer's disease; Amyloid protein; Amyloid plaque; Apolipoprotein E

Indexed keywords

AMYLOID BETA PROTEIN; APOLIPOPROTEIN A; EPITOPE;

ADULT; AGED; ALLELE; ALZHEIMER DISEASE; AMINO TERMINAL SEQUENCE; AMYLOIDOSIS; ARTICLE; AUTOPSY; CONTROLLED STUDY; FEMALE; GENOTYPE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MALE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN LOCALIZATION; PROTEIN TRANSPORT; RISK FACTOR; TEMPORAL LOBE;

ADULT; AGED; AGED, 80 AND OVER; ALLELES; ALZHEIMER DISEASE; AMYLOID BETA-PROTEIN; AMYLOIDOSIS; APOLIPOPROTEINS E; EPITOPES; FEMALE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; PROTEIN BINDING; RISK FACTORS; SENILE PLAQUES; TEMPORAL LOBE;

EID: 27944496889     PISSN: 00016322     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00401-005-1053-1     Document Type: Article

References (52)

1. Agresti A (2002) Categorial data analysis. Wiley, Hoboken
2. Allsop D, Landon M, Kidd M, Lowe JS, Reynolds GP, Gardner A (1986) Monoclonal antibodies raised against a subsequence of senile plaque core protein react with plaque cores, plaque periphery and cerebrovascular amyloid in Alzheimer's disease. Neurosci Lett 68:252-256 10.1016/ 0304-3940(86)90152-7
3. American Psychiatric Association (1994) Diagnostic and statistical manual of mental disorders, Washington DC
4. Bales KR, Verina T, Dodel RC, Du Y, Altstiel L, Bender M, Hyslop P, Johnstone EM, Little SP, Cummins DJ, Piccardo P, Ghetti B, Paul SM (1997) Lack of apolipoprotein E dramatically reduces amyloid beta-peptide deposition. Nat Genet 17:263-264 9354781
5. Braak H, Braak E (1991) Neuropathological stageing of Alzheimer-related changes. Acta Neuropathol 82:239-259 10.1007/BF00308809
6. Braak H, Braak E (1991) Demonstration of amyloid deposits and neurofibrillary changes in whole brain sections. Brain Pathol 1:213-216 1669710
7. Braak H, Braak E (1992) The human entorhinal cortex: Normal morphology and lamina-specific pathology in various diseases. Neurosci Res 15:6-31 10.1016/0168-0102(92)90014-4
8. Cho HS, Hyman BT, Greenberg SM, Rebeck GW (2001) Quantitation of apoE domains in Alzheimer disease brain suggests a role for apoE in Abeta aggregation. J Neuropathol Exp Neurol 60:342-349 11305869
9. Costa DA, Nilsson LN, Bales KR, Paul SM, Potter H (2004) Apolipoprotein is required for the formation of filamentous amyloid, but not for amorphous Abeta deposition, in an AbetaPP/PS double transgenic mouse model of Alzheimer's disease. J Alzheimers Dis 6:509-514
10. Cummings BJ, Cotman CW (1995) Image analysis of beta-amyloid load in Alzheimer's disease and relation to dementia severity. Lancet 346:1524-1528 10.1016/S0140-6736(95)92053-6
11. Drouet B, Fifre A, Pincon-Raymond M, Vandekerckhove J, Rosseneu M, Gueant JL, Chambaz J, Pillot T (2001) ApoE protects cortical neurones against neurotoxicity induced by the non-fibrillar C-terminal domain of the amyloid-beta peptide. J Neurochem 76:117-127 10.1046/ j.1471-4159.2001.00047.x
12. Esiri MM, Hyman BT, Beyreuther K, Masters CL (1997) Ageing and dementia. In: Graham DI, Lantos PL (eds) Greenfields neuropathology, 6th edn. Arnold, London, pp 153-233
13. Gearing M, Schneider JA, Robbins RS, Hollister RD, Mori H, Games D, Hyman BT, Mirra SS (1995) Regional variation in the distribution of apolipoprotein E and A beta in Alzheimer's disease. J Neuropathol Exp Neurol 54:833-841 7595656
14. Ghebremedhin E, Braak H, Braak E, Sahm J (1998) Improved method facilitates reliable APOE genotyping of genomic DNA extracted from formaldehyde-fixed pathology specimens. J Neurosci Methods 79:229-231 10.1016/S0165-0270(97)00197-0
15. Gowing E, Roher AE, Woods AS, Cotter RJ, Chaney M, Little SP, Ball MJ (1994) Chemical characterization of A beta 17-42 peptide, a component of diffuse amyloid deposits of Alzheimer disease. J Biol Chem 269:10987-10990 8157623
16. Gylys KH, Fein JA, Tan AM, Cole GM (2003) Apolipoprotein E enhances uptake of soluble but not aggregated amyloid-beta protein into synaptic terminals. J Neurochem 84:1442-1451 10.1046/j.1471-4159.2003.01643.x
17. Higgins LS, Murphy GM Jr, Forno LS, Catalano R, Cordell B (1996) P3 beta-amyloid peptide has a unique and potentially pathogenic immunohistochemical profile in Alzheimer's disease brain. Am J Pathol 149:585-596 8701997
18. Hsu SM, Raine L, Fanger H (1981) Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J Histochem Cytochem 29:577-580 6166661
19. Insausti R, Amaral DG (2004) Hippocampal Formation. In: Paxinos G, Mai JK (eds) The human nervous system. Elsevier, London, pp 872-914
20. Iqbal K, Braak H, Braak E, Grundke-Iqbal I (1993) Silver labeling of Alzheimer neurofibrillary changes and brain beta-amyloid. J Histotechnol 16:335-342
21. Iwatsubo T, Odaka A, Suzuki N, Mizusawa H, Nukina N, Ihara Y (1994) Visualization of A beta 42(43) and A beta 40 in senile plaques with end-specific A beta monoclonals: Evidence that an initially deposited species is A beta 42(43). Neuron 13:45-53 10.1016/0896-6273(94)90458-8
22. Iwatsubo T, Saido TC, Mann DM, Lee VM, Trojanowski JQ (1996) Full-length amyloid-beta [1-42(43)] and amino-terminally modified and truncated amyloid-beta 42(43) deposit in diffuse plaques. Am J Pathol 149:1823-1830 8952519
23. Kang DE, Pietrzik CU, Baum L, Chevallier N, Merriam DE, Kounnas MZ, Wagner SL, Troncoso JC, Kawas CH, Katzman R, Koo EH (2000) Modulation of amyloid beta-protein clearance and Alzheimer's disease susceptibility by the LDL receptor-related protein pathway. J Clin Invest 106:1159-1166 11067868
24. Kim KS, Miller DL, Sapienza VJ, Chen C-MJ, Bai C, Grundke-Iqbal I, Currie JR, Wisniewski HM (1988) Production and characterization of monoclonal antibodies reactive to synthetic cerebrovascular amyloid peptide. Neurosci Res Commun 2:121-130
25. Koistinaho M, Lin S, Wu X, Esterman M, Koger D, Hanson J, Higgs R, Liu F, Malkani S, Bales KR, Paul SM (2004) Apolipoprotein E promotes astrocyte colocalization and degradation of deposited amyloid-beta peptides. Nat Med 10:719-726 10.1038/nm1058
26. Lalowski M, Golabek A, Lemere CA, Selkoe DJ, Wisniewski HM, Beavis RC, Frangione B, Wisniewski T (1996) The "nonamyloidogenic" p3 fragment (amyloid beta17-42) is a major constituent of Down's syndrome cerebellar preamyloid. J Biol Chem 271:33623-33631 10.1074/ jbc.271.52.33623
27. Lemere CA, Blusztajn JK, Yamaguchi H, Wisniewski T, Saido TC, Selkoe DJ (1996) Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: Implications for initial events in amyloid plaque formation. Neurobiol Dis 3:16-32 10.1006/nbdi.1996.0003
28. Masters CL, Simms G, Weinman NA, Multhaup G, McDonald BL, Beyreuther K (1985) Amyloid plaque core protein in Alzheimer disease and Down syndrome. Proc Natl Acad Sci USA 82:4245-4249 3159021
29. Mazur-Kolecka B, Kowal D, Sukontasup T, Dickson D, Frackowiak J (2004) The effect of oxidative stress on amyloid precursor protein processing in cells engaged in beta-amyloidosis is related to apolipoprotein E genotype. Acta Neuropathol 108:287-294 10.1007/s00401-004-0890-7
30. Mirra SS, Heyman A, McKeel D, Sumi SM, Crain BJ, Brownlee LM, Vogel FS, Hughes JP, van Belle G, Berg L (1991) The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 41:479-486 2011243
31. Namba Y, Tomonaga M, Kawasaki H, Otomo E, Ikeda K (1991) Apolipoprotein E immunoreactivity in cerebral amyloid deposits and neurofibrillary tangles in Alzheimer's disease and kuru plaque amyloid in Creutzfeldt-Jakob disease. Brain Res 541:163-166 10.1016/ 0006-8993(91)91092-F
32. Naslund J, Haroutunian V, Mohs R, Davis KL, Davies P, Greengard P, Buxbaum JD (2000) Correlation between elevated levels of amyloid beta-peptide in the brain and cognitive decline. JAMA 283:1571-1577 10.1001/jama.283.12.1571
33. Nishiyama E, Iwamoto N, Ohwada J, Arai H (1997) Distribution of apolipoprotein E in senile plaques in brains with Alzheimer's disease: investigation with the confocal laser scan microscope. Brain Res 750:20-24 10.1016/S0006-8993(96)01329-7
34. Rebeck GW, Reiter JS, Strickland DK, Hyman BT (1993) Apolipoprotein E in sporadic Alzheimer's disease: Allelic variation and receptor interactions. Neuron 11:575-580 10.1016/0896-6273(93)90070-8
35. Sadowski M, Pankiewicz J, Scholtzova H, Ripellino JA, Li Y, Schmidt SD, Mathews PM, Fryer JD, Holtzman DM, Sigurdsson EM, Wisniewski T (2004) A synthetic peptide blocking the apolipoprotein E/beta-amyloid binding mitigates beta-amyloid toxicity and fibril formation in vitro and reduces beta-amyloid plaques in transgenic mice. Am J Pathol 165:937-948 15331417
36. Saido TC, Iwatsubo T, Mann DM, Shimada H, Ihara Y, Kawashima S (1995) Dominant and differential deposition of distinct beta-amyloid peptide species, A beta N3(pE), in senile plaques. Neuron 14:457-466 10.1016/ 0896-6273(95)90301-1
37. Saido TC, Yamao-Harigaya W, Iwatsubo T, Kawashima S (1996) Amino- and carboxyl-terminal heterogeneity of beta-amyloid peptides deposited in human brain. Neurosci Lett 215:173-176 10.1016/0304-3940(96)12970-0
38. Schmechel DE, Saunders AM, Strittmatter WJ, Crain BJ, Hulette CM, Joo SH, Pericak-Vance MA, Goldgaber D, Roses AD (1993) Increased amyloid beta-peptide deposition in cerebral cortex as a consequence of apolipoprotein E genotype in late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:9649-9653 8415756
39. Strittmatter WJ, Weisgraber KH, Huang DY, Dong LM, Salvesen GS, Pericak-Vance M, Schmechel D, Saunders AM, Goldgaber D, Roses AD (1993) Binding of human apolipoprotein E to synthetic amyloid beta peptide: isoform-specific effects and implications for late-onset Alzheimer disease. Proc Natl Acad Sci USA 90:8098-8102 8367470
40. Thal DR, Glas A, Schneider W, Schober R (1997) Differential pattern of beta-amyloid, amyloid precursor protein and apolipoprotein E expression in cortical senile plaques. Acta Neuropathol 94:255-265 10.1007/ s004010050701
41. Thal DR, Arendt T, Waldmann G, Holzer M, Zedlick D, Rüb U, Schober R (1998) Progression of neurofibrillary changes and PHF-tau in end-stage Alzheimer's disease is different from plaque and cortical microglial pathology. Neurobiol Aging 19:517-525 10.1016/S0197-4580(98)00090-6
42. Thal DR, Sassin I, Schultz C, Haass C, Braak E, Braak H (1999) Fleecy amyloid deposits in the internal layers of the human entorhinal cortex are comprised of N-terminal truncated fragments of Abeta. J Neuropathol Exp Neurol 58:210-216 10029103
43. Thal DR, Rüb U, Schultz C, Sassin I, Ghebremedhin E, Del Tredici K, Braak E, Braak H (2000) Sequence of Abeta-protein deposition in the human medial temporal lobe. J Neuropathol Exp Neurol 59:733-748 10952063
44. Thal DR, Schultz C, Dehghani F, Yamaguchi H, Braak H, Braak E (2000) Amyloid beta-protein (Abeta)-containing astrocytes are located preferentially near N-terminal-truncated Abeta deposits in the human entorhinal cortex. Acta Neuropathol 100:608-617 10.1007/s004010000242
45. Thal DR, Rüb U, Orantes M, Braak H (2002) Phases of Abeta-deposition in the human brain and its relevance for the development of AD. Neurology 58:1791-1800 12084879
46. The National Institute on Aging (1997) Consensus recommendations for the postmortem diagnosis of Alzheimer's disease. The National Institute on Aging, and Reagan Institute Working Group on Diagnostic Criteria for the Neuropathological Assessment of Alzheimer's Disease. Neurobiol Aging 18: S1-2 10.1016/S0197-4580(97)00057-2
47. Wild-Bode C, Yamazaki T, Capell A, Leimer U, Steiner H, Ihara Y, Haass C (1997) Intracellular generation and accumulation of amyloid beta-peptide terminating at amino acid 42. J Biol Chem 272:16085-16088 10.1074/ jbc.272.26.16085
48. Wisniewski HM, Sadowski M, Jakubowska-Sadowska K, Tarnawski M, Wegiel J (1998) Diffuse, lake-like amyloid-beta deposits in the parvopyramidal layer of the presubiculum in Alzheimer disease. J Neuropathol Exp Neurol 57:674-683 9690671
49. Wisniewski T, Frangione B (1992) Apolipoprotein E: A pathological chaperone protein in patients with cerebral and systemic amyloid. Neurosci Lett 135:235-238 10.1016/0304-3940(92)90444-C
50. Wisniewski T, Castano EM, Golabek A, Vogel T, Frangione B (1994) Acceleration of Alzheimer's fibril formation by apolipoprotein E in vitro. Am J Pathol 145:1030-1035 7977635
51. Yamaguchi H, Ishiguro K, Sugihara S, Nakazato Y, Kawarabayashi T, Sun X, Hirai S (1994) Presence of apolipoprotein E on extracellular neurofibrillary tangles and on meningeal blood vessels precedes the Alzheimer beta-amyloid deposition. Acta Neuropathol 88:413-419 7847069
52. Yamaguchi H, Sugihara S, Ogawa A, Saido TC, Ihara Y (1998) Diffuse plaques associated with astroglial amyloid beta protein, possibly showing a disappearing stage of senile plaques. Acta Neuropathol 95:217-222 10.1007/s004010050790